Title: Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer – a pilot study
Authors: SCHEIDHAUER KLEMENSSEIDL C.BRUCHERTSEIFER FRANKAPOSTOLIDIS CHRISTOSAUTENRIETH M.KURTZ FHORN THOMASSCHWAIGER M.GSCHWEND J.E.D’ALESSANDRIA CALOPFOB CSENEKOWITSCH-SCHMIDTKE R.MORGENSTERN ALFRED
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 44 no. S2 p. S130
Publisher: SPRINGER
Publication Year: 2017
JRC N°: JRC106724
ISSN: 1619-7070
URI: https://link.springer.com/journal/259/44/2/suppl/page/1
http://publications.jrc.ec.europa.eu/repository/handle/JRC106724
Type: Articles in periodicals and books
Abstract: Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.